ArticleWorld journal of gastrointestinal oncology2013
Hilar cholangiocarcinoma.
Article in World journal of gastrointestinal oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 21 citations in OpenAlex.
- Cholangiocarcinoma: a review of the literature and future directions in therapy.Hepatobiliary surgery and nutrition · 2022Review
- A case series of hilar cholangiocarcinoma: A single surgeon experience over 20-years.Annals of medicine and surgery (2012) · 2021Article
- Preoperative prediction of curative surgery of perihilar cholangiocarcinoma by combination of endoscopic ultrasound and computed tomography.United European gastroenterology journal · 2018Article
- Retinoid X receptor α enhances human cholangiocarcinoma growth through simultaneous activation of Wnt/β-catenin and nuclear factor-κB pathways.Cancer science · 2015Article
- The prognostic potential and oncogenic effects of PRR11 expression in hilar cholangiocarcinoma.Oncotarget · 2015Article
- Imaging and interventions in hilar cholangiocarcinoma: A review.World journal of radiology · 2015Review
- Placement of ¹²⁵I seed strands and stents for a type IV Klatskin tumor.World journal of gastroenterology · 2015Article
- Use of an autologous liver round ligament flap zeros postoperative bile leak after curative resection of hilar cholangiocarcinoma.PloS one · 2015Article
- Overexpression of Sig1R is closely associated with tumor progression and poor outcome in patients with hilar cholangiocarcinoma.Medical oncology (Northwood, London, England) · 2014Article
- Multimodal treatment strategies for advanced hilar cholangiocarcinoma.Langenbeck's archives of surgery · 2014Review
- Hilar cholangiocarcinoma: diagnosis, treatment options, and management.Hepatobiliary surgery and nutrition · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hilar cholangiocarcinoma (HC) is a rare tumor. It accounts for 2/3 of the tumors of the biliary tract. Untreated, prognosis is very poor. Surgery is the only therapy that offers the possibility of cure but is technically very complex. With recent improvements in the therapeutic strategies applied by multidisciplinary teams, survival rates in the different series currently range from 25% to 45%. A group of experts devoted to HC (pathologists, gastroenterologists, radiologists, surgeons and oncologists) have reviewed and updated every open question in HC in a special issue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.